Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Capital Leases (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Capital Leases readings, the most recent being $122000.0 for Q3 2025.

  • On a quarterly basis, Capital Leases fell 35.11% to $122000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $122000.0, a 35.11% decrease, with the full-year FY2024 number at $122000.0, down 47.19% from a year prior.
  • Capital Leases hit $122000.0 in Q3 2025 for Aligos Therapeutics, roughly flat from $122000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $261000.0 in Q4 2021 to a low of $53000.0 in Q3 2021.
  • Median Capital Leases over the past 5 years was $188000.0 (2023), compared with a mean of $175421.1.
  • Biggest five-year swings in Capital Leases: surged 228.3% in 2022 and later tumbled 47.19% in 2024.
  • Aligos Therapeutics' Capital Leases stood at $261000.0 in 2021, then dropped by 11.88% to $230000.0 in 2022, then increased by 0.43% to $231000.0 in 2023, then tumbled by 47.19% to $122000.0 in 2024, then changed by 0.0% to $122000.0 in 2025.
  • The last three reported values for Capital Leases were $122000.0 (Q3 2025), $122000.0 (Q2 2025), and $122000.0 (Q1 2025) per Business Quant data.